Cognitive Outcomes in Cancer: Recent Advances and Challenges

Guest Editors:

Prof. Dr. Diane Von Ah
College of Nursing, The Ohio State University, Columbus, OH, USA

Prof. Dr. Alexandre Chan
Clinical Pharmacy, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA, USA

Prof. Dr. Brenna C. McDonald
Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA

Deadline for manuscript submissions:
closed (15 September 2023)

Message from the Guest Editors

Dear Colleagues,

Cancer-related cognitive impairment (CRCI), formerly known as 'chemobrain', is a prevalent, bothersome, and potentially debilitating problem for survivors for their lifespan. Despite its prevalence, research is relatively limited, and questions remain regarding associated risk factors, underlying mechanisms, and potential interventions to address CRCI. Research is needed to fully understand patients most at risk for CRCI for informed decision-making.

We encourage contributions that are focused on, but not limited to, the following themes:

- Biomarkers
- Genetic markers
- Associated Risk Factors including social determinants of health and/or vulnerable populations (e.g., children, adolescent and young adults, and older cancer survivors)
- Neuroimaging
- Cognitive Rehabilitation—Cognitive Training, Cognitive Behavioral Therapy, etc.
- Stress-reducing therapies—Mindfulness-based stress reduction, exercise, etc.
- Pharmacological interventions
- Impact on health-related quality of life

We look forward to receiving your contributions.

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us